Combination therapy isn’t always the answer, here’s why doctors reconsider

Combination therapy—using two or more treatments together—is not automatically better than a single treatment. Doctors reconsider it when evidence shows that added medicines offer little extra benefit, increase side effects or interactions, complicate care, or no longer fit a patient’s goals. The balance depends on the condition and the specific treatments: in some settings, combinations improve outcomes, while in others, simplifying therapy can reduce harm and make treatment easier to follow. Evidence from hypertension, diabetes, and cancer illustrates why decisions should be individualized and reviewed over time.

Combination therapy benefits and trade-offs

Combination therapy is the use of multiple therapeutic agents or approaches at the same time to prevent, control, or treat a condition. The U.S. National Cancer Institute uses the term for treatment with more than one anticancer drug, and the broader clinical concept also includes combinations such as medicines plus behavioral therapy or medicines that act through different biological pathways.

The rationale is that treatments may work better together, address different disease mechanisms, or allow lower doses of individual medicines. But every added treatment can also contribute adverse effects, interactions, cost, and workload. The U.S. Centers for Disease Control and Prevention reported that 24% of U.S. adults used three or more prescription drugs in 2017–2020, illustrating how common multi-drug treatment is—not that every such regimen is inappropriate. The clinical question is whether each component still provides enough benefit to justify its burden.

Additive, synergistic, and fixed-dose combinations

An additive combination produces an effect roughly equal to the sum of its components; a synergistic combination produces a greater-than-expected effect; and a fixed-dose combination places multiple active ingredients in one product. These categories describe different ways therapies may be paired, but a plausible mechanism or convenient pill does not by itself prove that a regimen improves outcomes that matter to patients. Clinical trials and ongoing review are needed to establish benefits, risks, and the appropriate duration.

Why more treatment can mean more risk

Each additional medicine may introduce side effects or interact with other prescriptions, over-the-counter products, or supplements. A regimen can also become harder to take correctly when it involves multiple doses, timing rules, or monitoring requirements. The World Health Organization has estimated that around half of people with chronic diseases in developed countries do not take medicines as prescribed, although adherence varies by condition and setting. Complexity is only one factor, but it is a practical reason clinicians periodically ask whether every medicine remains necessary.

Doctors reconsider combination therapy when the balance changes

Reconsideration means a structured review of whether the expected benefits of a treatment combination still outweigh its harms and burdens. It may lead to continuing the regimen, adjusting doses, substituting a medicine, or stopping one component under clinical supervision. The National Institute for Health and Care Excellence (NICE) describes medication review as a structured examination of a person’s medicines, with attention to whether treatment is effective, appropriate, and aligned with the person’s needs and preferences.

The review is especially important after a new diagnosis, a change in kidney or liver function, a significant side effect, a hospital stay, or a shift in treatment goals. Doctors may also revisit a combination when updated evidence changes recommendations or when a condition is controlled and the treatment burden has become disproportionate. The aim is not to reduce medicines reflexively; it is to make each component earn its place in the plan.

Polypharmacy and deprescribing

Polypharmacy generally refers to the use of multiple medicines, often five or more, although definitions differ among researchers and health systems. It can be appropriate for people with several conditions, but the chance of duplicative treatment, interactions, and difficult dosing may rise as regimens grow. Deprescribing is the supervised process of reducing or stopping a medicine when its potential harms outweigh its benefits or when it no longer matches a patient’s goals. It should be planned with a clinician, since some medicines require gradual tapering and abrupt discontinuation can be dangerous.

Shared decisions and monitoring

A sound decision weighs disease severity, evidence for each drug, side effects, interactions, the patient’s priorities, and what monitoring is feasible. Patients can help by keeping an up-to-date medicine list and reporting all prescriptions, supplements, and nonprescription products. When a combination is changed, clinicians may set a follow-up date, identify symptoms or measurements to watch, and explain when to seek help. Patients should not stop or alter prescribed medicines on their own.

Examples show why combination therapy is condition-specific

Evidence does not support a universal rule for or against combination treatment. The value of a combination depends on the diagnosis, the drugs involved, the patient’s risk profile, and the outcome being targeted. Examples from cardiovascular care, diabetes, and cancer show how the same principle—compare added benefit with added burden—can lead to different decisions.

Hypertension: combinations can improve control, but require review

For many people with high blood pressure, combining medicines from different classes can lower blood pressure more effectively than maximizing a single drug, because the medicines act through distinct pathways. The 2017 American College of Cardiology and American Heart Association guideline noted that two first-line agents from different classes may be considered for adults with stage 2 hypertension, particularly when blood pressure is substantially above the target. That does not mean every patient should remain on the same combination indefinitely: low blood pressure, dizziness, electrolyte changes, kidney-function changes, or a change in health status may prompt dose adjustment or a different plan.

Type 2 diabetes: treatment should follow goals and changing health

Type 2 diabetes often requires more than one medicine over time because the condition can progress and treatments target different aspects of glucose regulation and cardiovascular or kidney risk. The American Diabetes Association’s Standards of Care emphasize person-centered selection based on factors such as cardiovascular disease, heart failure, kidney disease, weight, hypoglycemia risk, cost, and preferences. A clinician may add a medicine when a single treatment is insufficient, but may also reduce or replace one if it causes hypoglycemia, is poorly tolerated, or no longer fits the patient’s health priorities. The appropriate combination is therefore not determined by blood sugar alone.

Cancer: combinations may be powerful, but toxicity matters

Cancer regimens often combine drugs to attack tumors through different mechanisms or reduce the likelihood that resistant cells survive. The National Cancer Institute explains that combination chemotherapy may use drugs with different ways of acting and different side effects. Because toxicities can accumulate, oncology teams weigh potential tumor response and survival benefit against risks such as infection, nerve damage, nausea, or harm to organs. In some cases, treatment is modified or stopped because the disease has responded, side effects are serious, or the expected benefit no longer justifies continued exposure.

A practical framework for reviewing a treatment combination

A medication review works best when it is specific, evidence-based, and shared between clinician and patient. The following questions can help organize a conversation without replacing professional medical advice:

  • What is the purpose of each medicine or treatment, and what outcome is it intended to improve?
  • Is there evidence that the combination benefits this patient’s condition and risk profile?
  • Are there side effects, interactions, duplicate therapies, or monitoring concerns?
  • Has the patient’s diagnosis, health status, or treatment goal changed?
  • If a component is reduced or stopped, what is the plan for tapering, follow-up, and monitoring?

A chart could help compare the expected benefit, known risks, and practical burden of each component, but the assessment should be individualized rather than reduced to a simple score. Decisions should account for uncertainty, patient preferences, and the consequences of both continuing and changing treatment.

Conclusion: combination therapy should be reviewed, not assumed

Combination therapy can be essential when multiple treatments provide meaningful, complementary benefits. Doctors reconsider it when evidence, side effects, interactions, regimen complexity, or patient goals shift the balance. Polypharmacy and deprescribing are not opposites of good care: together, they underscore the need to use enough treatment to achieve worthwhile outcomes without adding medicines that no longer help. Patients should discuss concerns and possible changes with their health-care team, and should never stop prescribed treatment without guidance.

Sources: U.S. Centers for Disease Control and Prevention, “Prescription Drug Use Among Adults Aged 40–79 in the United States and Canada,” NCHS Data Brief No. 470, 2023, https://www.cdc.gov/nchs/products/databriefs/db470.htm; World Health Organization, “Adherence to Long-Term Therapies: Evidence for Action,” 2003, https://iris.who.int/handle/10665/42682; National Institute for Health and Care Excellence, “Medicines Optimisation: The Safe and Effective Use of Medicines to Enable the Best Possible Outcomes,” NG5, 2015, https://www.nice.org.uk/guidance/ng5; Whelton PK et al., “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults,” Hypertension, 2018, https://doi.org/10.1161/HYP.0000000000000065; American Diabetes Association Professional Practice Committee, “Standards of Care in Diabetes—2025,” Diabetes Care, 2025, https://diabetesjournals.org/care/issue/48/Supplement_1; National Cancer Institute, “Combination Chemotherapy,” https://www.cancer.gov/about-cancer/treatment/types/chemotherapy/combination-therapy-fact-sheet.